We analyzed one assertion regarding apitegromab at 10 mg/kg every four weeks in adults with overweight or obesity, and found no studies that contradict it. The evidence we’ve reviewed so far suggests that total latent myostatin levels stabilize by week 16, which may indicate the drug is interacting with its intended biological target as designed [1]. Latent myostatin is a protein that, when active, can limit muscle growth. By binding to it, apitegromab may prevent it from doing so — a mechanism thought to help preserve or increase muscle mass. The stabilization of these levels by week 16 implies the drug’s effect has reached a steady state, meaning the body is no longer adjusting to the dose. This pattern is often seen in medications that work through consistent, targeted pathways. We did not find any data showing that levels continued to rise, fall, or fluctuate after week 16, nor did we find evidence comparing this outcome to other doses or populations. The single assertion we reviewed comes from a single source and lacks details about how the measurements were made, who was studied, or whether other factors like diet or activity influenced the results. Because we only have one assertion — and no studies with opposing findings — we cannot say whether this pattern holds across different groups or over longer periods. It also doesn’t tell us if this change in latent myostatin leads to any noticeable physical outcomes, like increased strength or reduced fat. What we’ve found so far is a single signal that the drug may be doing what it was designed to do at this dose and schedule. More data is needed to understand how consistent this effect is, and whether it matters for health or body composition.